Breakthrough for New Treatment for Chronic Lyme Disease

Breakthrough for New Treatment for Chronic Lyme Disease

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has expanded upon a research collaboration with Dr. Leona Gilbert at the Department of Biological and Environmental Sciences of the University of Jyvaskyla, Finland to further characterize the activity of bisphosphocins™ against Borrelia burgdorferi.

According to a press release,  this collaboration has been established to build on initial findings demonstrating the effectiveness of bisphosphocin™ Nu-3 in killing multiple life forms of B. burgdorferi.  The research collaboration is intended to fully determine the mechanism of action, characterize the bactericidal activity against the various forms of B. burgdorferi, and select a lead bisphosphocin™ candidate for potential pre-clinical development.

This could be big news around the world as large funded labs are now applying for grants and funding to develop effective treatments based on the snowballing numbers of affected people worldwide.

The press release admits that B. burgdorferi (amongst various species of Borrelia) is the pathogen responsible for Lyme disease, a chronic multisystem difficult to treat debilitating disease that can have long term health consequences for patients.  The reported patient population is large and growing rapidly.

The collaboration:

About Lakewood-Amedex, Inc.
Lakewood-Amedex is a privately held clinical-stage biopharmaceutical company developing a broad portfolio of innovative novel-approach anti-infective products in the treatment of serious infectious diseases, improving patient outcomes and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, VRE, NDM-1, and biofilm strains.

The Company’s products and technology are covered by an extensive patent portfolio consisting of 74 issued and 13 pending patents.  The Company’s lead product, Nu-3, a first-in-class antimicrobial, is being developed as a treatment for bacterial and fungal infections.  

Lakewood-Amedex is also developing orally available ‘gene silencing’ nRNA therapeutics for the treatment of various viral indications, oncology applications, inflammatory conditions and other chronic human diseases.

About University of Jyvaskyla
The University of Jyvaskyla, Finland, is a nationally and internationally significant research university and an expert on education that focuses on human and natural sciences. 

The University of Jyvaskyla has 15,000 students, and the number of staff is 2,600. The Department of Biological and Environmental Sciences offers high-quality teaching and is founded on excellent research activities.  

Dr. Leona Gilbert Research Group, a part of Cell and Molecular Biology in the Department of Biological and Environmental Science, provides teaching and undertakes research in a field bordering with biochemistry, chemistry, biotechnology, molecular and cell biology and nano-science.

The main focus of Dr. Leona Gilbert’s Research Group is to “Understanding Microbial Effectors that Contribute to Chronic Diseases”. This research group provides a framework for the analysis of a common adverse viral / bacterial infection and its contribution to chronic autoimmune diseases.

(Visited 192 times, 1 visits today)
Subscribe to Jenna's Lyme Blog
Yes, I want to subscribe. I understand I will only receive one email each month when there are new posts.
This entry was posted in Chronic Lyme Disease, Lyme Disease News, Research and Development and tagged , , . Bookmark the permalink.

4 Responses to Breakthrough for New Treatment for Chronic Lyme Disease

  1. Gail says:

    This article has interesting news, but it looks like the draft NOT the final version! Broken and repetitive sentences etc. Please fix it! 🙂

  2. Kim Wood says:

    Jenna,
    Thank you for your continued efforts for the Lyme Community at large! I attempted to sign the petition and read that it has been archived due to not meeting signature requirements. There were over 5000 signatures. Do you know if we can reopen the same petition and try to meet the requirement?
    Thank you,
    Kim

    • Jenna Seaver says:

      Hi Kim –

      Thanks for commenting! I feel badly that I didn’t realize what a short window we had. It shows we need to get better organized and set up a communication chain through our state associations and through blogs! I am not sure about future attempts to get this petition going again. but will keep people posted.

  3. Susan says:

    This sounds great! Please keep us informed. Thanks for all the work you do.

Leave a Reply

Your email address will not be published. Required fields are marked *